CoChat
Sign Up
Cited by 1,346Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Open access
Buse, John B., Henry, Robert R., Han, Jenny, Kim, Dennis D., Fineman, Mark S., Baron, Alain D., for the Exenatide-113 Clinical Study Group·2004·Diabetes Care
DOI 10.2337/diacare.27.11.2628
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE—This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy. RESEARCH DESIGN AND METHODS—This was a triple-blind, placebo-controlled, 30-week study conducted at 101 sites in the U.S. After a 4-week, single-blind, placebo lead-in period, 377 subjects were randomized (60% men, age 55 ± 11 years, BMI 33 ± 6 kg/m2, HbA1c 8.6 ± 1.2% [±SD]) and began 4 weeks at 5 μg subcutaneous exenatide twice daily (before breakfast and dinner; arms A and B) or placebo. Subsequently, subjects in arm B were escalated to 10 μg b.i.d. exenatide. All subjects continued sulfonylurea therapy. RESULTS—At week 30, HbA1c changes from baseline were −0.86 ± 0.11, −0.46 ± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms, respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA1c > 7% (n = 237), 41% (10 μg), 33% (5 μg), and 9% (placebo) achieved HbA1c ≤ 7% (P < 0.001). Fasting plasma glucose concentrations decreased in the 10-μg arm compared with placebo (P < 0.05). Subjects in the exenatide arms had dose-dependent progressive weight loss, with an end-of-study loss in the 10-μg exenatide arm of −1.6 ± 0.3 kg from baseline (P < 0.05 vs. placebo). The most frequent adverse events were generally mild or moderate and gastrointestinal in nature. No severe hypoglycemia was observed. CONCLUSIONS—Exenatide significantly reduced HbA1c in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea. Exenatide was generally well tolerated and was associated with weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.27.11.2628

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Sorted by citations

Items 701–800 of 998

Related

See all

Metadata

Authors
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • University of California San Diego (US)
  • Amylin Pharmaceuticals, San Diego, California
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2004-11-01
Volume
27
Issue
11
Pages
2628-2635
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.27.11.2628
OpenAlex
W1986085856
Cited by
1,346
References
38
Citations by year
2026: 18 · 2025: 22 · 2024: 17 · 2023: 7 · 2022: 13 · 2021: 24 · 2020: 20 · 2019: 16 · 2018: 19 · 2017: 30 · 2016: 53 · 2015: 46 · 2014: 76 · 2013: 79 · 2012: 120
FWCI
56.01
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Amylin Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
exenatide, exendin-4, type 2 diabetes, sulfonylureas, glycemic control, HbA1c, incretin mimetics, dose escalation, weight loss, fasting blood glucose, gastrointestinal adverse effects, hypoglycemia, combination therapy, long-term efficacy and safety
MeSH terms
Exenatide, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fasting, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Peptides, Proinsulin, Sulfonylurea Compounds, Venoms, Weight Loss, Treatment Failure, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review